Table 2.
Clinicopathological parameters of the study population and expression profiles of INPP5A, HLA-G1, IL-10, and MMP-21
Parameters | No. | INPP5A expression | HLA-G1 expression | MMP-21 expression | IL-10 expression | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-/ | -/ | -/ | -/ | -/ | -/ | -/ | -/ | ||||||
Gender | |||||||||||||
Male | 32 | 30 | 2 | 24 | 8 | 13 | 19 | 15 | 17 | ||||
Female | 24 | 21 | 3 | 19 | 5 | 9 | 15 | 8 | 13 | ||||
Grade of differentiation | |||||||||||||
P.D. | 10 | 7 | 3 | 8 | 2 | 5 | 5 | 2 | 6 | ||||
M.D. | 34 | 33 | 1 | 25 | 9 | 13 | 21 | 15 | 19 | ||||
W.D. | 12 | 11 | 1 | 10 | 2 | 4 | 8 | 7 | 5 | ||||
Tumor location | |||||||||||||
Lower | 23 | 20 | 3 | 21 | 2 | 10 | 13 | 10 | 13 | ||||
Middle | 32 | 31 | 1 | 21 | 11 | 12 | 20 | 15 | 17 | ||||
Upper | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||
Depth of tumor invasion | |||||||||||||
T1 | 3 | 1 | 2 | 3 | 0 | 1 | 2 | 1 | 2 | ||||
T2 | 8 | 8 | 0 | 5 | 3 | 2 | 6 | 5 | 3 | ||||
T3 | 45 | 42 | 3 | 35 | 10 | 19 | 26 | 20 | 25 | ||||
LNM | |||||||||||||
No metastasis | 31 | 27 | 4 | 23 | 8 | 12 | 19 | 11 | 20 | ||||
Node metastasis | 25 | 24 | 1 | 20 | 5 | 10 | 15 | 15 | 10 | ||||
Stage of tumor progression | |||||||||||||
I | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | ||||
IIa | 29 | 26 | 3 | 21 | 8 | 11 | 18 | 11 | 18 | ||||
IIb | 5 | 3 | 2 | 3 | 2 | 0 | 5 | 3 | 2 | ||||
III | 21 | 21 | 0 | 18 | 3 | 10 | 11 | 12 | 9 | ||||
IV | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
P.D., poorly differentiated; M.D., moderately differentiated; W.D., well differentiated; , overexpression; , underexpression ; -, normal